CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Quantitative analysis of SARS-CoV-2 antibodiesWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1185 SARS-CoV-2 diagnostic rapid test Wiki 1.00
drug591 Hydroxychloroquine Wiki 0.11
drug1016 Placebo Wiki 0.08

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Herd Immunity Study SARS-CoV-2-CZ-Preval

The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on direct detection of SARS-CoV- 2, including individuals with a subclinical course of the disease.

NCT04401085 COVID SARS-CoV 2 Diagnostic Test: SARS-CoV-2 diagnostic rapid test Diagnostic Test: Quantitative analysis of SARS-CoV-2 antibodies

Primary Outcomes

Description: Statistically, the primary objective is formulated as an estimate of the cumulative prevalence of SARS-CoV-2 positive individuals in geographically defined subpopulations of the Czech Republic with declared reliability of +/- 2%. For this primary objective, the required sample size in individual geographical cohorts is calculated. The positivity of SARS-CoV-2 individuals who have not been diagnosed with COVID-19 by a standard route of the detection will be assessed by the presence of specific IgM or IgG antibodies in the blood (antibody tests).

Measure: Estimation of the actual prevalence of SARS-CoV-2 positive persons in the Czech Republic.

Time: May 2020

Secondary Outcomes

Description: The proportion of SARS-CoV-2 positive persons who, according to the questionnaire, will not report any or minimal symptoms in the anamnesis.

Measure: Estimation of the proportion of people with a subclinical course of the disease

Time: May 2020

Measure: Estimation of the cumulative prevalence of the disease and the proportion of people with a subclinical course differences between subcohorts according to demographic, social and clinically relevant stratifications.

Time: May 2020

Description: The estimation will be calculated according to the prevalence of the disease in the population after excluding contraindications to blood donation (age, health status, etc.).

Measure: Estimation of the proportion of persons suitable for the donation of convalescent plasma

Time: May 2020


No related HPO nodes (Using clinical trials)